Monoclonal antibody successes in the clinic
Article Abstract:
Therapeutic monoclonal antibodies (mAbs) have developed into a beneficial and profitable group of products, although it had an inauspicious beginning in the 1980s. Monoclonal antibodies comprise the majority of recombinant proteins currently in the clinic, with more than 150 products in studies sponsored by companies located worldwide.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2005
User Contributions:
Comment about this article or add new information about this topic:
The patentability of antibodies in the United States
Article Abstract:
Two court cases, Noelle v. Lederman and SmithKline Beecham v. Apotex, in the US attracts attention on the patentability of antibodies. The subtleties surrounding application of the US patent statues 35 USC [section] 102, 103, 112 greatly affect the patentability of antibodies.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2005
User Contributions:
Comment about this article or add new information about this topic: